Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.
Giovanni Corona, Clotilde Sparano, Marilina Romeo et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) on male sexual hormones and function in overweight and obese individuals. The study found that GLP1-RAs significantly increased total and calculated free testosterone levels, independent of weight loss, while SGLT2is showed limited data. A total of 427 subjects were included across the studies.
Key findings
- GLP1-RAs significantly increased total and calculated free testosterone levels.
- Both GLP1-RAs and SGLT2is improved body composition and metabolic profiles.
- GLP1-RAs led to positive outcomes in erectile function.
- Testosterone replacement therapy showed better results than GLP1-RAs for orgasm and sexual satisfaction.
Why it matters
Understanding the effects of GLP1-RAs and SGLT2is on male sexual health is crucial for managing obesity-related hypogonadism and sexual dysfunction, which can significantly impact quality of life.